((自动化翻译由路透提供，请见免责声明 )) (更新)
10月22日 - ** 基因组医疗公司Sangamo Therapeutics 股价上涨 33.6%，达到1.22美元的8个多月新高
** 该公司称，美国食品和药物管理局（FDA）已同意将正在进行的早中期研究数据作为加速批准其治疗法布里病的实验性基因疗法的主要依据
** 据古根海姆分析师称，FDA 的反馈意见表明，该机构 "在寻求广泛推进基因疗法的过程中具有监管灵活性"。
** 法布里病是一种遗传性疾病，由人体细胞中的一种脂肪堆积引起。
** 不需要额外的注册研究来支持基因疗法isaralgagene civaparvovec的加速审批--SGMO公司
** SGMO表示，研究的完整数据集将于2025年上半年公布，预计将于2025年下半年提交申请。
** 包括盘中涨幅在内，该股今年累计涨幅超过一倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.